About this trial
This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.
Eligibility criteria
Qualifiers
Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV
Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project.
Ca 125 which will have to be less than 200
ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2).
Disqualifiers
Partial response with persistence of ascites or pleural effusion.
With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates >2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).
Trial design
Treatments tested in this trial
- Interval Cytoreduction Surgery
Treatment groups
Sponsors and collaborators
Instituto Nacional de Cancerologia de Mexico
Lead sponsor
None in Three Research Centre
Sponsor institution